Your cutting-edge expert with the resources to manage your pharmacy program effectively, contain cost, and be accountable for the results. We are the next generation; we are the solution.
Dispense As Written Prescription Instructions and Their Impact on Plan Sponsors and Participants by Joe Schmidt, MBA, Vice President | Team Lead Before the
Common Sense Management of Narcolepsy and Cataplexy by Bob Kordella, R.Ph., MBA, Chief Clinical Officer The Mayo Clinic provides a simple definition of narcolepsy and
November 30, 2020:Where We Are Today And When Will New Vaccines Be Approved? by Bob Kordella, R.Ph., MBA, Chief Clinical Officer Worldwide there were 48
Pharmacy renegotiation through Excelsior Solutions Annual Pharmacy Savings of $6.3M (23%
Using Data to Identify Fraudulent Claims Pharmacy Reimbursement of $26,000 Challenge
Opioid Case Study Annual Savings of $192,000 Challenge Member filling pain
With increasing specialty drug costs, pharmacy benefit managers,health plans and industry experts often tout the use of biosimilarsas a strategy to lower cost. In 2013,
As you may recall, back in March of this year, Eli Lilly announced that they would begin to manufacture and sell an authorized generic version
The news that the FDA approved the first A-rated (meaning that pharmacists may freely substitute it without physician approval) generic form of Advair Diskus on
Hello, everyone, and welcome to this edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap: ICER has published its latest report on
Hello, everyone, and welcome to this week’s edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap: ICER has posted a Draft Scoping
Hello, everyone, and welcome to this week’s edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap: ICER released a Final Evidence Report
© Copyright 2019 Excelsior Solutions • Privacy Policy • All Rights Reserved